Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Corcept Therapeutics Inc (CORT) Common Stock USD0.001

Sell:$20.30 Buy:$25.70 Change: $0.12 (0.58%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$20.30
Buy:$25.70
Change: $0.12 (0.58%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:$20.30
Buy:$25.70
Change: $0.12 (0.58%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Contact details

Address:
149 Commonwealth Dr
MENLO PARK
94025-1133
United States
Telephone:
+1 (650) 3273270
Website:
www.corcept.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CORT
ISIN:
US2183521028
Market cap:
$2.37 billion
Shares in issue:
115.93 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joseph Belanoff
    President, Chief Executive Officer, Co-Founder, Director
  • Atabak Mokari
    Chief Financial Officer, Treasurer
  • Joseph Lyon
    Chief Accounting Officer
  • Hazel Hunt
    Chief Scientific Officer
  • William Guyer
    Chief Development Officer
  • Sean Maduck
    Chief Commercial Officer
  • Gary Robb
    Chief Business Officer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.